

Juan Undurraga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/937053/publications.pdf>

Version: 2024-02-01

72
papers

2,545
citations

331259

21
h-index

197535

49
g-index

84
all docs

84
docs citations

84
times ranked

3335
citing authors

#	ARTICLE	IF	CITATIONS
1	Emotional intelligence: a comparison between patients after first episode mania and those suffering from chronic bipolar disorder type I. <i>Psychological Medicine</i> , 2023, 53, 3065-3076.	2.7	2
2	The incidence of non-affective psychotic disorders in Chile between 2005 and 2018: results from a national register of over 30 000 cases. <i>Psychological Medicine</i> , 2022, 52, 914-923.	2.7	9
3	Effects of socioeconomic status in cognition of people with schizophrenia: results from a Latin American collaboration network with 1175 subjects. <i>Psychological Medicine</i> , 2022, 52, 2177-2188.	2.7	13
4	Functional Dysconnectivity in Ventral Striatocortical Systems in 22q11.2 Deletion Syndrome. <i>Schizophrenia Bulletin</i> , 2022, 48, 485-494.	2.3	2
5	Gender, age and geographical representation over the past 50 years of schizophrenia research. <i>Psychiatry Research</i> , 2022, 307, 114279.	1.7	3
6	Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 36-50.	2.2	4
7	Effects of Socioeconomic Status in Cognition of People with Schizophrenia: Results From a Latin American Collaboration Network with 1175 Subjects - Corrigendum. <i>Psychological Medicine</i> , 2022, , 1-1.	2.7	0
8	Obesity and brain structure in schizophrenia â€“ ENIGMA study in 3021 individuals. <i>Molecular Psychiatry</i> , 2022, 27, 3731-3737.	4.1	17
9	The enduring gap in educational attainment in schizophrenia according to the past 50 years of published research: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2022, 9, 565-573.	3.7	12
10	Childhood adversity increases risk of psychotic experiences in patients with substance use disorder. <i>Psychiatry Research</i> , 2022, 316, 114733.	1.7	4
11	Structural brain abnormalities in schizophrenia in adverse environments: examining the effect of poverty and violence in six Latin American cities. <i>British Journal of Psychiatry</i> , 2021, 218, 112-118.	1.7	10
12	Pharmacogenetics in Psychiatry: Perceived Value and Opinions in a Chilean Sample of Practitioners. <i>Frontiers in Pharmacology</i> , 2021, 12, 657985.	1.6	4
13	Brain Network Architecture Intricately Linked to Morphological Abnormalities in Major Psychiatric Disorders. <i>Biological Psychiatry</i> , 2021, 89, S229-S230.	0.7	0
14	Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. <i>Journal of Psychopharmacology</i> , 2021, 35, 890-900.	2.0	47
15	Predictors of clozapine discontinuation at 2â€“ years in treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2021, 235, 102-108.	1.1	6
16	Antidepressant responses in direct comparisons of melancholic and non-melancholic depression. <i>Journal of Psychopharmacology</i> , 2020, 34, 1335-1341.	2.0	9
17	Melancholia: does this ancient concept have contemporary utility?. <i>International Review of Psychiatry</i> , 2020, 32, 466-470.	1.4	10
18	T159. STRUCTURAL BRAIN ABNORMALITIES IN SCHIZOPHRENIA IN ADVERSE ENVIRONMENTS: EXAMINING THE EFFECT OF POVERTY AND VIOLENCE IN SIX LATIN AMERICAN CITIES. <i>Schizophrenia Bulletin</i> , 2020, 46, S291-S292.	2.3	0

#	ARTICLE	IF	CITATIONS
19	A 12-month prospective study on the time to hospitalization and clinical management of a cohort of bipolar type I and schizoaffective bipolar patients. <i>European Psychiatry</i> , 2019, 61, 1-8.	0.1	4
20	T67. CASE CONTROL STUDY OF CANNABIS USE IN FIRST EPISODE PSYCHOSIS IN CHILE. <i>Schizophrenia Bulletin</i> , 2019, 45, S230-S230.	2.3	0
21	Lithium treatment for unipolar major depressive disorder: Systematic review. <i>Journal of Psychopharmacology</i> , 2019, 33, 167-176.	2.0	50
22	High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 1382-1388.	0.9	5
23	Imaging Social and Environmental Factors as Modulators of Brain Dysfunction: Time to Focus on Developing Non-Western Societies. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 8-15.	1.1	14
24	Early treatment resistance in a Latin-American cohort of patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 199, 380-385.	1.1	12
25	T222. EARLY TREATMENT RESISTANCE IN A LATIN-AMERICAN COHORT OF PATIENTS WITH SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S202-S203.	2.3	0
26	F127. GLOBAL RECOVERY IN A FIRST EPISODE PSYCHOSIS PROGRAM IN SOUTH AMERICA. <i>Schizophrenia Bulletin</i> , 2018, 44, S269-S270.	2.3	0
27	S101. CLINICAL FACTORS ASSOCIATED WITH CANNABIS USE IN A CHILEAN SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS. <i>Schizophrenia Bulletin</i> , 2018, 44, S364-S364.	2.3	0
28	Clinical characterization of rapid cycling bipolar disorder: Association with attention deficit hyperactivity disorder. <i>Journal of Affective Disorders</i> , 2018, 240, 187-192.	2.0	14
29	Depressive symptoms are associated with higher morning plasma cortisol in primary care subjects. <i>Neuroendocrinology Letters</i> , 2018, 39, 288-293.	0.2	1
30	Duration of untreated psychosis and acute remission of negative symptoms in a South American first-episode psychosis cohort. <i>Microbial Biotechnology</i> , 2017, 11, 77-82.	0.9	14
31	Morbidity in Depressive Disorders. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 65-72.	4.0	51
32	Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2017, 31, 1184-1189.	2.0	38
33	Tricyclic and selective serotonin-reuptake-inhibitor antidepressants compared with placebo in randomized trials for acute major depression. <i>Journal of Psychopharmacology</i> , 2017, 31, 1624-1625.	2.0	0
34	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 757-777.	0.9	286
35	Psychoeducation in bipolar disorder with a SIMPLE smartphone application: Feasibility, acceptability and satisfaction. <i>Journal of Affective Disorders</i> , 2016, 200, 58-66.	2.0	110
36	Implementing Psychosocial Evidence-Based Practices in Mental Health: Are We Moving in the Right Direction?. <i>Frontiers in Psychiatry</i> , 2015, 6, 51.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Making sense of DSM-5 mania with depressive features. Australian and New Zealand Journal of Psychiatry, 2015, 49, 540-549.	1.3	20
38	Los costos y consumo de recursos sanitarios asociados a episodios maníacos en la práctica clínica diaria: el estudio MANACOR. Revista De Psiquiatría Y Salud Mental, 2015, 8, 55-64.	1.0	12
39	Risk factors for rapid cycling in bipolar disorder. Bipolar Disorders, 2015, 17, 549-559.	1.1	29
40	Predictors of functional outcome after a manic episode. Journal of Affective Disorders, 2015, 182, 121-125.	2.0	16
41	The real world cost and health resource utilization associated to manic episodes: The MANACOR study. Revista De Psiquiatría Y Salud Mental (English Edition), 2015, 8, 55-64.	0.2	1
42	Overview of Antidepressant Treatment of Bipolar Depression. Focus (American Psychiatric Publishing), 2015, 13, 102-112.	0.4	2
43	Self-monitoring and psychoeducation in bipolar patients with a smart-phone application (SIMPLE) project: design, development and studies protocols. BMC Psychiatry, 2015, 15, 52.	1.1	57
44	e-HCL-32: a useful, valid and user friendly tool in the screening of bipolar II disorder. Comprehensive Psychiatry, 2015, 56, 283-288.	1.5	9
45	Strategies for Improving Randomized Trial Evidence for Treatment of Bipolar Disorder. , 2015, , 599-622.		0
46	Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. International Journal of Neuropsychopharmacology, 2014, 17, 1343-1352.	1.0	28
47	Early Medication Discontinuation on Long-term Recovery Outcome in First-Episode Psychosis. JAMA Psychiatry, 2014, 71, 206.	6.0	9
48	Pharmacological treatment of bipolar depression. Advances in Psychiatric Treatment, 2014, 20, 193-201.	0.6	11
49	Stratified medicine for mental disorders. European Neuropsychopharmacology, 2014, 24, 5-50.	0.3	152
50	¿Es bipolar disorder an endocrine condition? Glucose abnormalities in bipolar disorder. Acta Psychiatrica Scandinavica, 2014, 129, 73-74.	2.2	16
51	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	4.0	579
52	Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. Journal of Affective Disorders, 2013, 144, 191-198.	2.0	28
53	¿Debería considerarse la obesidad un factor limitante para el tratamiento con clozapina?. Revista De Psiquiatría Y Salud Mental, 2013, 6, 75-79.	1.0	5
54	Should obesity be a limiting factor for clozapine treatment?. Revista De Psiquiatría Y Salud Mental (English Edition), 2013, 6, 75-79.	0.2	2

#	ARTICLE	IF	CITATIONS
55	Re-analysis of the earliest controlled trials of imipramine. <i>Journal of Affective Disorders</i> , 2013, 147, 451-454.	2.0	7
56	Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>European Neuropsychopharmacology</i> , 2013, 23, 305-316.	0.3	24
57	Overview of antidepressant treatment of bipolar depression. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1673-1685.	1.0	70
58	Randomized, Placebo-Controlled Trials of Antidepressants for Acute Major Depression: Thirty-Year Meta-Analytic Review. <i>Neuropsychopharmacology</i> , 2012, 37, 851-864.	2.8	198
59	Olanzapine in Schizophrenia and Affective Disorders. <i>Drug Safety</i> , 2012, 35, 1185-1186.	1.4	3
60	Origins of Psychiatric Hospitalization in Medieval Spain. <i>Psychiatric Quarterly</i> , 2012, 83, 419-430.	1.1	23
61	Age at onset versus family history and clinical outcomes in 1,665 international bipolar disorder patients. <i>World Psychiatry</i> , 2012, 11, 40-46.	4.8	138
62	Clozapine and agranulocytosis in Spain: Do we have a safer population? A 5-year haematologic follow-up. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2012, 5, 37-42.	0.2	3
63	Bipolar depression: Clinical correlates of receiving antidepressants. <i>Journal of Affective Disorders</i> , 2012, 139, 89-93.	2.0	48
64	Predominant recurrence polarity among 928 adult international bipolar I disorder patients. <i>Acta Psychiatrica Scandinavica</i> , 2012, 125, 293-302.	2.2	119
65	Suicidal Risk Factors in Bipolar I and II Disorder Patients. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 778-782.	1.1	81
66	Risk Factors for Antidepressant-Related Switch to Mania. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e271-e276.	1.1	58
67	The Authors' Reply. <i>Drug Safety</i> , 2012, 35, 1183-1184.	1.4	2
68	Olanzapine in Schizophrenia and Affective Disorders. <i>Drug Safety</i> , 2012, 35, 1185-1186.	1.4	1
69	Remission and functioning after two years undergoing Long-Acting Injectable Risperidone (LAIR) in recent-onset schizophrenia. <i>European Psychiatry</i> , 2011, 26, 1344-1344.	0.1	0
70	Brain germinoma presenting as a first psychotic episode in an adolescent male. <i>European Child and Adolescent Psychiatry</i> , 2010, 19, 741-742.	2.8	6
71	Treatment of Narcolepsy Complicated by Psychotic Symptoms. <i>Psychosomatics</i> , 2009, 50, 427-428.	2.5	9
72	Consent, decisional capacity and guardianship in mental health research. <i>Wellcome Open Research</i> , 0, 7, 183.	0.9	1